Agios Pharm Stock Investor Sentiment

AGIO Stock  USD 57.51  1.83  3.29%   
About 66 percent of all Agios Pharm's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Agios Pharm suggests that quite a few traders are confidant. Agios Pharm's investing sentiment overview a quick insight into current market opportunities from investing in Agios Pharm. Many technical investors use Agios Pharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

66

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Agios Pharm's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Agios Pharm.

Agios Historical Sentiment

Although Agios Pharm's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Agios, such as negative comments on social media and news outlets, may cause fear in the market and push Agios Pharm's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Agios.
  

Agios Pharm Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Agios Pharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Acquisition by Capello Jeffrey D of 1976 shares of Agios Pharm subject to Rule 16b-3
Yahoo News
over three months ago at finance.yahoo.com         
AGIO GPT AI UK Ltd Launches Revolutionary AGIO-GPT, Pioneering Accessible AI Innovation
Yahoo News
over three months ago at news.google.com         
Agios Pharmaceuticals, Inc. Shares Bought by First Trust Advisors LP - MarketBeat
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 1913 shares by T Washburn of Agios Pharm at 31.75 subject to Rule 16b-3
Macroaxis News
over three months ago at gurufocus.com         
Insider Sale CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over three months ago at benzinga.com         
Updated Time Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June ...
benzinga news
over three months ago at finance.yahoo.com         
Updated Time Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June ...
Yahoo News
over three months ago at investing.com         
Agios Pharmaceuticals executive sells over 60k in company stock
Investing News at Macroaxis
over three months ago at investing.com         
Disposition of 12115 shares by Goff Brian of Agios Pharm at 48.84 subject to Rule 16b-3
Investing News at Macroaxis
over three months ago at zacks.com         
Agios Up 21 percent on Upbeat Data From 2nd Thalassemia Study
zacks News
over three months ago at benzinga.com         
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?
benzinga news
over three months ago at benzinga.com         
Disposition of 1362 shares by T Washburn of Agios Pharm at 44. subject to Rule 16b-3
benzinga news
over three months ago at statnews.com         
STAT Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows
news
over three months ago at globenewswire.com         
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary End...
Macroaxis News: globenewswire.com
over three months ago at simplywall.st         
Companies Like Agios Pharmaceuticals Are In A Position To Invest In Growth
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Agios Pharm that are available to investors today. That information is available publicly through Agios media outlets and privately through word of mouth or via Agios internal channels. However, regardless of the origin, that massive amount of Agios data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Agios Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Agios Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Agios Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Agios Pharm alpha.

Agios Pharm Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Alibaba, Eli Lilly lead Fridays morning market cap stock movers
09/27/2024
2
Agios Pharmaceuticals Upgraded to Hold at StockNews.com
10/17/2024
3
Analysts Are Optimistic Well See A Profit From Agios Pharmaceuticals, Inc.
10/25/2024
4
Agios Pharmaceuticals Inc Q3 2024 Earnings EPS Surpasses Estimates, Revenue at 9.0 Million
10/31/2024
5
Agios Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong Cash Position and ...
11/01/2024
6
Agios Pharmaceuticals Is Posting Healthy Earnings, But It Is Not All Good News
11/07/2024
7
Disposition of 1500 shares by Ballal Rahul D. of Agios Pharm at 59.21 subject to Rule 16b-3
11/08/2024
8
Agios Pharmaceuticals director sells shares worth 1.12 million
11/12/2024
9
ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc
11/15/2024
10
Disposition of 300 shares by Foster-cheek Kaye I of Agios Pharm at 32.21 subject to Rule 16b-3
11/19/2024
11
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
11/20/2024
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Agios Pharm Hype Analysis, Agios Pharm Correlation and Agios Pharm Performance.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.66
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.